Position of the Transparency Council – Elvanse
At its meeting on 21 October 2024, the Transparency Council adopted position No. 111/2024 on the appropriateness of issuing reimbursement approvals for the drug Elvanse for the indication of attention deficit hyperactivity disorder (ADHD) (ICD-10: F90.1)